Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-09-08
1997-08-05
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 435 691, C07K 14435, A61K 3817
Patent
active
056542704
ABSTRACT:
The present invention provides a method of inhibiting an activity of a cell regulatory factor which includes contacting the cell regulatory factor with a purified polypeptide, the polypeptide including the cell regulatory factor binding domain of a protein which is characterized by a leucine-rich repeat of about 24 amino acids. The present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, to bind TGF-.beta.. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors. The present invention further relates to methods for the prevention or reduction of scarring by administering decorin or a functional equivalent of decorin to a wound. The methods are particularly useful for dermal wounds resulting from burns, injuries or surgery. In addition, the present invention includes pharmaceutical compositions containing decorin or its functional equivalent and a pharmaceutically acceptable carrier useful in such methods. Finally, methods for preventing or inhibiting pathological conditions by administering decorin are also provided.
REFERENCES:
Shah, M., et al. (1991) J. Cell. Biochem. 15(suppl. F): 198, abstract No. Q423.
Takeuchi, Y., et al. (1994) J. Biol. Chem. 269: 32634-8.
Hausser, H., et al. (1994) FEBS Lett. 353: 243-5.
Oldberg, A., et al. (1989) EMBO J. 8: 2601-04.
Montesano, R., et al. (1985) Proc. Natl. Acad. Sci. USA 85: 4894-97.
Moriyama, K., et al. (1991) Matrix 11: 190-96.
Adzick, N. S., et al. (1992) Ann. Surg. 215: 3-7.
Lorenz, H. P., et al. (1993) Western J. Med. 159: 350-55.
Border et al., "Antagonists of transforming growth factor-.beta.: A novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis" Kidney Int. 41:566-570 (1992).
Sporn, M.B., et al. (1992) J. Cell Biol. 119 (2): 1017-21.
Border, W.A., et al. (1992) J. Clin. Invest. 90: 1-7.
Castellot et al., "Inhibition of Vascular Smooth Muscle Cell Growth by Endothelial Cell-Derived Heparin" J. Biol. Chem. 257:11256-11260 (1982).
Vogel et al., "Specific Inhibition of Type I and Type II collagen Fibrillogenesis by the Small Proteoglycan of Tendon" Biochem. J. 223:587-597 (1984).
Massague et al., "Cellular Receptors for Type Beta Transforming Growth Factor" J. Biol. Chem. 260:2636-2645 (1985).
Fritze et al., "An Antiproliferative Heparin Sulfate Species Produced by Postconfluent Smooth Muscle Cells" J. Cell Biol. 100:1041-1049 (1985).
Krusius et al., "Primary Structure of an Extracellular Matrix Proteoglycan Core Protein Deduced from Cloned cDNA" Proc. Natl. Acad. Sci. USA 83:7683-7687 (1986).
Castellot et al., "Glomerular Endothelial Cells Secrete a heparinlike Inhibitor and a Peptide Stimulator of Mesangial Cell Proliferation" Am. J. Pathol. 125:493-500 (1986).
Cheifetz et al., "The Transforming Growth Factor-Beta System, a Complex Pattern of Cross-Reactive Ligands and Receptors" Cell 48:409-415 (1987).
Ishihara et al., "Involvement of Phosphatidylinositol and Insulin in the Cordinate Regulation of Protecheparan Sulfate Metabolism and Hepatocyte Growth" J. Biol. Chem. 262:4706-4716 (1987).
Day et al., "Molecular Cloning and Sequence Analysis of the cDNA for Small Proteoglycan II of Bovine Bone" Biochem. J. 248:801-805 (1987).
Patthy, "Detecting Homology of Distantly Related Proteins with Consensus Sequences" J. Mol. Biol. 198:567-577 (1987).
Bassols et al., "Transforming Growth Factor Beta Regulates the Expression and Structure of Extracellular Matrix Chondroitin/Dermatan Sulfate Proteoglycans" J. Biol. Chem. 263:3039-3045 (1988).
Segarini et al., "The High Molecular Weight Receptor to Transforming Growth Factor-Beta Contains Glycosaminoglycan Chains" J. Biol. Chem. 263:8366-8370 (1988).
Cheifetz et al., "Heterodimeric Transforming Growth Factor Beta" J. Biol. Chem. 263:10783-10789 (1988a).
Cheifetz et al., "The Transforming Growth Factor-Beta Receptor Type III is a Membrane Proteoglycan" J. Biol. Chem. 263:16984-16991 (1988b).
Fisher et al., "Deduced Protein Sequence of Bone Small Proteoglycan I (Biglycan) shows Homology with Proteoglycan II (Decorin) and Several Nonconnective Tissue Proteins in a Variety of Species" J. Biol. Chem. 264:4571-4576 (1989).
Andres et al., "Membrane-anchored and Soluble Forms of Betaglycan, a Polymorphic Proteoglycan that Binds Transforming Growth Factor-Beta" J. Cell. Biol. 109:3137-3145 (1989).
Kanzaki et al., "TGF-Beta 1 Binding Protein: A Component of the Large Latent Complex of TGF-Beta 1 with Muliple Repeat Sequences" Cell 61:1051-1061 (1990).
Brennan et al., "Effect of a Proteoglycan Produced by Rat Tumor Cells on Their Adhesion to Fibronectin-Collagen Substrata 1" Cancer Res. 43:4302-4307 (1983).
Brennan et al., "Chondroitin/Dermatan Sulfate Proteoglycan in Human Fetal Membranes" J. of Biol. Chem. 259:13742-13750 (1984).
Kresse et al., "Glycosaminoglycan-free Small Proteoglycan Core Protein Secreted by Fibroblasts from a Patient with a Syndrome Resembling Progeroid" Am. J. Hum. Genet. 41, (1987).
Yamaguchi et al., "Expression of Human Proteoglycan in Chinese Hamster Ovary Cells Inhibits Cell Proliferation" Nature 336:244-246 (1988).
Yamaguchi et al., "Negative Regulation of Transforming Growth Factor-Beta by the Proteoglycan Decorin" Nature 346:281-284 (1990).
Pearson et al., "The NH2-Terminal Amino Acid Sequence of Bovine Skin Proteodermatan Sulfate" The Journal of Biol. Chem. 258:15101-15104 (1983).
Ruoslahti, "Structure and Biology of Proteoglycans" Ann. Rev. Cell Biol. 4:229-255 (1988).
Longaker Michael T.
Ruoslahti Erkki I.
Whitby David J.
Fitzgerald David L.
La Jolla Cancer Research Foundation
LandOfFree
Use of fibromodulin to prevent or reduce dermal scarring does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of fibromodulin to prevent or reduce dermal scarring, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of fibromodulin to prevent or reduce dermal scarring will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1074805